Ayala Pharmaceuticals
AP
About
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing novel small molecule therapeutics for patients with rare tumors and aggressive cancers. Their pipeline targets specific genetic alterations that drive tumor growth and resistance to existing therapies.
Key facts
At-a-glance profile data
- Website
- ayalapharma.com
- Headquarters
- Jerusalem, Israel
- Founded
- 2017
- Total funding
- $72M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 19 Feb 2021 | Series C | $25M | - |
| 28 May 2019 | Series B | $30M | Novartis Venture Fund |
| 11 Apr 2018 | Series A | $17M | Israel Biotech Fund |
Tech stack
Detected on ayalapharma.com, last scanned 10 Sept 2026. Run your own scan
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Ayala Pharmaceuticals raised?
Ayala Pharmaceuticals has raised a total of $72M in funding. The most recent round on record is Series C.